CNS Pharmaceuticals, Inc. entered into Securities Purchase Agreements for the sale of 1,425,000 shares of common stock in a registered direct offering, with a concurrent private placement of unregistered warrants to purchase up to an aggregate of 1,425,000 shares of common stock.